These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 15684701)
1. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Konstan MW; Davis PB; Wagener JS; Hilliard KA; Stern RC; Milgram LJ; Kowalczyk TH; Hyatt SL; Fink TL; Gedeon CR; Oette SM; Payne JM; Muhammad O; Ziady AG; Moen RC; Cooper MJ Hum Gene Ther; 2004 Dec; 15(12):1255-69. PubMed ID: 15684701 [TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. Knowles MR; Noone PG; Hohneker K; Johnson LG; Boucher RC; Efthimiou J; Crawford C; Brown R; Schwartzbach C; Pearlman R Hum Gene Ther; 1998 Jan; 9(2):249-69. PubMed ID: 9472784 [TBL] [Abstract][Full Text] [Related]
3. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. Knowles MR; Hohneker KW; Zhou Z; Olsen JC; Noah TL; Hu PC; Leigh MW; Engelhardt JF; Edwards LJ; Jones KR N Engl J Med; 1995 Sep; 333(13):823-31. PubMed ID: 7544439 [TBL] [Abstract][Full Text] [Related]
4. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Noone PG; Hohneker KW; Zhou Z; Johnson LG; Foy C; Gipson C; Jones K; Noah TL; Leigh MW; Schwartzbach C; Efthimiou J; Pearlman R; Boucher RC; Knowles MR Mol Ther; 2000 Jan; 1(1):105-14. PubMed ID: 10933918 [TBL] [Abstract][Full Text] [Related]
5. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Porteous DJ; Dorin JR; McLachlan G; Davidson-Smith H; Davidson H; Stevenson BJ; Carothers AD; Wallace WA; Moralee S; Hoenes C; Kallmeyer G; Michaelis U; Naujoks K; Ho LP; Samways JM; Imrie M; Greening AP; Innes JA Gene Ther; 1997 Mar; 4(3):210-8. PubMed ID: 9135734 [TBL] [Abstract][Full Text] [Related]
6. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. Zabner J; Cheng SH; Meeker D; Launspach J; Balfour R; Perricone MA; Morris JE; Marshall J; Fasbender A; Smith AE; Welsh MJ J Clin Invest; 1997 Sep; 100(6):1529-37. PubMed ID: 9294121 [TBL] [Abstract][Full Text] [Related]
7. Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hay JG; McElvaney NG; Herena J; Crystal RG Hum Gene Ther; 1995 Nov; 6(11):1487-96. PubMed ID: 8573621 [TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gill DR; Southern KW; Mofford KA; Seddon T; Huang L; Sorgi F; Thomson A; MacVinish LJ; Ratcliff R; Bilton D; Lane DJ; Littlewood JM; Webb AK; Middleton PG; Colledge WH; Cuthbert AW; Evans MJ; Higgins CF; Hyde SC Gene Ther; 1997 Mar; 4(3):199-209. PubMed ID: 9135733 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Flotte TR; Zeitlin PL; Reynolds TC; Heald AE; Pedersen P; Beck S; Conrad CK; Brass-Ernst L; Humphries M; Sullivan K; Wetzel R; Taylor G; Carter BJ; Guggino WB Hum Gene Ther; 2003 Jul; 14(11):1079-88. PubMed ID: 12885347 [TBL] [Abstract][Full Text] [Related]
15. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. Wilschanski M; Yahav Y; Yaacov Y; Blau H; Bentur L; Rivlin J; Aviram M; Bdolah-Abram T; Bebok Z; Shushi L; Kerem B; Kerem E N Engl J Med; 2003 Oct; 349(15):1433-41. PubMed ID: 14534336 [TBL] [Abstract][Full Text] [Related]
16. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Wagner JA; Messner AH; Moran ML; Daifuku R; Kouyama K; Desch JK; Manley S; Norbash AM; Conrad CK; Friborg S; Reynolds T; Guggino WB; Moss RB; Carter BJ; Wine JJ; Flotte TR; Gardner P Laryngoscope; 1999 Feb; 109(2 Pt 1):266-74. PubMed ID: 10890777 [TBL] [Abstract][Full Text] [Related]
17. Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications. Joseph PM; O'Sullivan BP; Lapey A; Dorkin H; Oren J; Balfour R; Perricone MA; Rosenberg M; Wadsworth SC; Smith AE; St George JA; Meeker DP Hum Gene Ther; 2001 Jul; 12(11):1369-82. PubMed ID: 11485629 [TBL] [Abstract][Full Text] [Related]
19. A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung. Crystal RG; Jaffe A; Brody S; Mastrangeli A; McElvaney NG; Rosenfeld M; Chu CS; Danel C; Hay J; Eissa T Hum Gene Ther; 1995 May; 6(5):643-66. PubMed ID: 7578401 [No Abstract] [Full Text] [Related]
20. Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Limberis M; Anson DS; Fuller M; Parsons DW Hum Gene Ther; 2002 Nov; 13(16):1961-70. PubMed ID: 12427306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]